Tagged with generics,

Sweden Orifarm is the largest supplier of parallel imported medicines in the EU and a fast-growing supplier of generic pharmaceuticals in the Nordic countries. Christian Vallentin, country manager of Orifarm Sweden, explains the intricacies of the parallel import business and generics market in Sweden, how to successfully compete in both areas,…

Egypt Dr Hany Mashaal, general manager for Egypt and the Rest of Middle East for Sun Pharma, explains the importance of Egypt for the Indian company, having recently opened a manufacturing facility in the country. He highlights the need for a faster drug registration process and gives an outlook at the…

Taiwan Chuan Lin, chairman of TTY Biopharm, one of Taiwan’s leading domestic biomedical players, highlights his ambition to lead the local success story onto the global stage. Chuan goes on to share the company’s transition strategy to leverage their innovative development platforms and manufacturing capabilities to be a partner of choice…

Spain Lab Seid is a family owned pharmaceutical company based in Barcelona, specialising in branded out of patent products in the field of women’s health. Seid’s general manager, Joaquín Vilá, discusses the turnaround of the company since taking over in 2011, and the strategy behind its consolidation around gynaecology. Vila also…

Spain Marc Comas, managing director of Accord Healthcare Iberia, highlights the footprint of the company as the leading generics and biosimilars player in the Spanish hospital sector and how his early strategy when founding the affiliate has set them up for long-term success. Furthermore, he points out the dynamics of the…

France Vincent Pont, president of Laboratoire Arrow, explains the company’s history, its collaboration with Aurobindo, the Indian generic pharmaceuticals group, the company’s unique positioning as a leader in the generic hospital sector, and its future growth strategies.   Generics companies need a wide portfolio to meet all of the generics needs…

France Bertrand de Lavenne, general manager of Mylan France, explains how the affiliate is positioned within the group’s operations and how the Mylan strategy is to be a key actor in connecting the health network around patient needs. De Lavenne also shares his view on the French pharmaceutical market and the…

France Pascal Brière, president of Biogaran, the leading French domestic player in generics, reflects on the development of the generic market since the 1999 Generic Substitution Act. Brière goes on to comment on Biogaran’s unique strategy of leveraging added solutions, international expansion, and biosimilars. He concludes with his thoughts on the…

France Jean-Louis Anspach, general manager of Teva France, elaborates on the affiliate’s transitional restructuring period as they make a turnaround effort in the face of group-wide challenges. Anspach goes on to explain what areas will be driving Teva forward while sharing his views on the French generic and biosimilar environment.  …

Japan Already established as one of the world’s leading markets for innovative and patented drugs, Japan is set to grow rapidly in 2019, partly as a result of a dramatic uptake in generics and biosimilars.   Japan’s pharmaceutical industry has long centred on strong innovation and patented drugs, but we are…

Korea Dr Byung Guk Yang, CEO of Daewoong Bio, explains the challenges the Korean healthcare system is facing and how his experience in the public sector now helps him lead a private sector company. He also offers his insights into Daewoong Bio’s diversified business model and highlights the need for internationalization.…

China In late 2018 China adopted a novel procurement scheme with the aim of dramatically cutting the amount being paid for generic drugs. The policy’s effect on pricing stands to hit domestic generic firms hardest unless they adapt their business models. Big Pharma could also lose out as their off-patent originators…